Aldeyra Ebit Over Time
| ALDX Stock | USD 4.94 0.14 2.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aldeyra Performance and Aldeyra Correlation. Aldeyra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aldeyra. If investors know Aldeyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aldeyra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Return On Assets (0.23) | Return On Equity (0.43) |
The market value of Aldeyra is measured differently than its book value, which is the value of Aldeyra that is recorded on the company's balance sheet. Investors also form their own opinion of Aldeyra's value that differs from its market value or its book value, called intrinsic value, which is Aldeyra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aldeyra's market value can be influenced by many factors that don't directly affect Aldeyra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aldeyra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aldeyra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aldeyra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Aldeyra and related stocks such as Tarsus Pharmaceuticals, LianBio ADR, and Travere Therapeutics Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARS | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (4.3 M) | (26.8 M) | (13.8 M) | (59.9 M) | (132.5 M) | (125.9 M) |
| TVTX | (18.3 K) | (12.8 K) | (30.2 M) | (14.2 M) | (58.4 M) | (46.5 M) | (23.1 M) | (47.5 M) | (82.3 M) | (99.8 M) | (169.7 M) | (213.3 M) | (320.1 M) | (364.8 M) | (346.5 M) |
| ETON | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (7.7 M) | (18.6 M) | (27.1 M) | (1.6 M) | (8.3 M) | (1.2 M) | (1.3 M) |
| VRDN | (3.1 M) | (3.1 M) | (3.1 M) | (446.2 K) | (7 M) | (11.2 M) | (9.7 M) | (26.4 M) | (32.1 M) | (42 M) | (110.2 M) | (79.4 M) | (129.4 M) | (235.1 M) | (223.3 M) |
| TERN | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (70.2 M) | (37 M) | (49.9 M) | (62 M) | (102.8 M) | (97.7 M) |
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (37.9 M) | (52.6 M) | (102.8 M) | (97.6 M) |
| BPMC | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (39.8 M) | (53 M) | (73.6 M) | (149.5 M) | (240.8 M) | (371.6 M) | 296.4 M | (641.1 M) | (535.5 M) | (482 M) | (457.9 M) |
| ETNB | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (26.6 M) | (49.4 M) | (89.7 M) | (100.1 M) | (134.7 M) | (128 M) |
| XFOR | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (21.9 M) | (32.3 M) | (42 M) | (51.7 M) | (59.9 M) | (87 M) | (89.6 M) | (107.9 M) | (102.5 M) |
| INZY | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (20.8 M) | (57 M) | (57 M) | (68.7 M) | (75.6 M) | (79.4 M) |
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (43.8 M) | (72.7 M) | (146.9 M) | (206.4 M) | (196.1 M) |
| HOOK | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (15.4 M) | (51.1 M) | (53.3 M) | (81.7 M) | (73.2 M) | (80.9 M) | (84.9 M) |
| PHAT | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (106.2 M) | (124.5 M) | (135.1 M) | (172.4 M) | (159.6 M) | (167.6 M) |
| LYRA | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (16.5 M) | (22.2 M) | (43.6 M) | (55 M) | (65.5 M) | (62.3 M) |
| CGEM | (699 K) | (699 K) | (699 K) | (699 K) | (128.8 K) | (95.4 K) | (197.4 K) | (14.6 M) | (14.6 M) | (22.3 M) | (60.3 M) | (68 M) | 151.3 M | (190.6 M) | (181.1 M) |
| BLRX | 6.2 M | (15.4 M) | (21.8 M) | (17.2 M) | (9.8 M) | (17.4 M) | (16.7 M) | (24.3 M) | (25.6 M) | (28.1 M) | (22.9 M) | (26 M) | (29.2 M) | (58.4 M) | (55.5 M) |
| ARDX | (7.9 M) | (7.9 M) | (7.9 M) | 641 K | (1.6 M) | (29.4 M) | (111.6 M) | (65.1 M) | (87.9 M) | (89.1 M) | (89.2 M) | (155.4 M) | (65.6 M) | (56.6 M) | (59.5 M) |
| LXRX | (12.8 M) | (118.7 M) | (102.4 M) | (107.2 M) | (85.5 M) | 10.8 M | (137.6 M) | (136 M) | (103.5 M) | 141.4 M | (44 M) | (87 M) | (99.2 M) | (164 M) | (155.8 M) |
| MCRB | (3 M) | (3 M) | (3 M) | (6.1 M) | (13.7 M) | (55.6 M) | (90.6 M) | (91.4 M) | (100.3 M) | (78.1 M) | (86.2 M) | (65.9 M) | (249.4 M) | (109.4 M) | (114.9 M) |
| IBRX | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (237.2 M) | (121.3 M) | (96.3 M) | (96.3 M) | (156.3 M) | (197.1 M) | (334.5 M) | (359.7 M) | (454.7 M) | (432 M) |
Aldeyra and related stocks such as Tarsus Pharmaceuticals, LianBio ADR, and Travere Therapeutics Ebit description
My Equities
My Current Equities and Potential Positions
| Aldeyra | ALDX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.94
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.